Burjeel Holdings launches new cancer institute in Abu Dhabi

BCI consolidates the group’s cancer care network across Abu Dhabi, Al Ain, Al Dhafra, Sharjah, and Dubai.

Healthcare services provider, Burjeel Holdings, has announced the launch of a new institute in Abu Dhabi dedicated to cancer care.

The Burjeel Cancer Institute (BCI) features a four-storey tower that offers private chemotherapy suites, speciality clinics, a dedicated breast cancer unit, and other patient-centric facilities.

Moreover, the institute offers treatments including targeted therapy and precision medicine, whilst integrating services for chemotherapy, immunotherapy, surgical oncology, stereotactic radiosurgery (SRS), and stereotactic body radiotherapy (SBRT).

“By integrating advanced diagnostic tools and cutting-edge treatments under one roof, we aim to provide a seamless and patient-centric experience,” BCI CEO, Humaid Al Shamsi, said.

In line with Al Shamsi’s statement, the BCI offers specialised diagnostic tests through OncoHelix-CoLab, utilising technologies such as next-generation sequencing (NGS), droplet digital PCR, and multi-colour flow cytometry.

“Our focus is on enhancing the quality of life for our patients and their families,” he added.